- Home
- SKE vs INDV Comparison
SKE vs INDV Comparison
Compare SKE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKE | INDV |
|---|---|---|
| Founded | 1979 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.7B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SKE | INDV |
|---|---|---|
| Price | $30.62 | $34.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 495.7K | ★ 1.7M |
| Earning Date | 05-12-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37,573.35 | N/A |
| P/E Ratio | ★ N/A | $20.65 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $15.43 | $22.22 |
| 52 Week High | $38.77 | $42.81 |
Technical Indicators
Market Signals| Indicator | SKE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 32.67 |
| Support Level | $30.42 | $32.06 |
| Resistance Level | $34.91 | $35.54 |
| Average True Range (ATR) | 1.18 | 0.84 |
| MACD | -0.47 | -0.00 |
| Stochastic Oscillator | 15.61 | 21.65 |
Price Performance
Historical ComparisonAbout SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).